ZFP36L1
ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Overview
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signalling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.90, affected pathway 0.31, genetic association 0.55, somatic mutation 0.48). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Malignant Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
- 1 · What it is
ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
- 2 · What goes wrong in cancer
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis.
- 3 · How drugs use it
No product in this corpus aims at ZFP36L1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1107 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q07352 (protein name, function text, keywords and locations (REST API)); CIViC gene ZFP36L1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000185650 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0)); IntOGen ZFP36L1 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signalling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes. Also induces the degradation of ARE-containing mRNAs even in absence of poly(A) tail. Binds to 3'-UTR ARE of numerous mRNAs. Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs). Location: Nucleus; Cytoplasm; Cytoplasmic granule; Cytoplasm, P-body (UniProt). Locus 14q24.1 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZFP36L1" OR ABSTRACT:"ZFP36L1" OR TITLE:"ZFP36 like 1 zinc finger CCCH-type" OR ABSTRACT:"ZFP36 like 1 zinc finger CCCH-type" OR TITLE:"mRNA decay activator protein ZFP36L1" OR ABSTRACT:"mRNA decay activator protein ZFP36L1" OR TITLE:"Berg36" OR ABSTRACT:"Berg36" OR TITLE:"ERF1" OR ABSTRACT:"ERF1" OR TITLE:"TIS11B" OR ABSTRACT:"TIS11B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZFP36L1, not a curated reading list.